Novo Nordisk Declares Levemir A Winner In U.S. Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.
You may also be interested in...
Novo Nordisk To Ramp Up Diabetes Sales Force In 2007
Novo Nordisk tells “The Pink Sheet” DAILY it has started recruiting reps; it intends to add 700 next year.
Novo Nordisk To Ramp Up Diabetes Sales Force In 2007
Novo Nordisk tells “The Pink Sheet” DAILY it has started recruiting reps; it intends to add 700 next year.
Novo Nordisk Levemir To Launch Within Next 12 Months
Long-acting insulin analogue clears FDA June 17 for treatment of type 1 and type 2 diabetes. Firm says approval makes it the only company in U.S. with a "full range" of short-acting and long-acting insulin analogues.